HIV persistence: defective virus copies accumulate rapidly after infection

PrEP update: EU approval, extended access for PROUD participants, TAF studies underway

Conference materials and online publications

September/October 2016: Volume 17 Number 9/10

July/August 2016: Volume 17 Number 7/8

21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

AIDS 2016: online access to conference programme

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

ZERO HIV transmissions in PARTNER study: most widely reported i-Base article

PrEP studies at AIDS 2016: includes first preclinical data with EFdA

Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study

Once-daily raltegravir at last available: 48 week results from ONCEMRK study

Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2

Dolutegravir is superior to boosted atazanavir in women in the ARIA study

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

Sub-Saharan African countries moving quickly to recommend “Treat All”

Efavirenz associated with suicide risk in analysis from START study

CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

Publications launched at AIDS 2016

8th International Workshop on HIV paediatrics, 15-16 July 2016, Durban, South Africa.

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

TB 2016, 16-17 July 2016, Durban, South Africa

Universal treatment of multi-drug resistant TB is possible within current budgets with generic production

Shortened nine-month MDR-TB treatment works well in children and adolescents

Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB

2016 Towards an HIV Cure Symposium, 16-17 July 2016, Durban, South Africa

17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 8-10 June 2016, Washington DC, USA

Modelling data might support use of low dose 400 mg efavirenz in pregnancy

Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery

BHIVA antiretroviral guidelines updated (2016)

PROUD study closes leaving participants without access to PrEP

EMA overcomes its own prejudice to approve PrEP in Europe: four years too late

NAT legal challenge forces NHS England to reopen process for PrEP: 45-day public consultation now online

Two large PrEP studies using two-month infusion of antibodies to prevent HIV infection: oral PrEP included for all participants

July/August 2016: Volume 17 Number 7/8


HTB supplement: 2016 Pipeline Report


Executive summary – HIV

Executive summary – tuberculosis

The antiretroviral pipeline 2016

Fit for purpose: antiretroviral treatment optimisation 2016

The paediatric antiretroviral pipeline

Preventive technologies: antiretroviral and vaccine development

Research toward a cure and immune-based and gene therapies

The tuberculosis diagnostics pipeline

The tuberculosis prevention pipeline

The tuberculosis treatment pipeline: activity, but no answers

The paediatric tuberculosis treatment pipeline: beyond pharmacokinetics and safety data

2016 hepatitis C virus (HCV) update

NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos

In Memory: Paul Blanchard

May/June 2016: Volume 17 Number 5/6

22nd Annual BHIVA Conference, 19-22 April 2016, Manchester

New HBV drugs and non-viral liver disease in HIV positive people

Non-AIDS mortality in England and Wales in HIV positive vs general population

High prevalence of multiple high-risk HPV infections in young HIV positive gay men

Anal cancer and HPV screening in HIV positive people

Increasing demand for community treatment information services

Non alcohol fatty acid liver disease: an emerging problem

HIV positive people on ART have impaired alveolar immunity

International Liver Congress (EASL) 2016, 13-18 April 2016, Barcelona

High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries

Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries

Post navigation